Close Menu

10X Genomics

 

10x Genomics, Inc. is an American company incorporated in 2012 that develops and manufactures integrated systems for whole genome sequencing, exome sequencing and single cell transcriptomics. Its headquarters are located in Pleasanton, California.

 

10X Genomics Company Profile  

 

President & CEO: Serge Saxonov

CEO photo:

 10X Genomics CEO photo - Serge Saxonov

Website: http://10xgenomics.com

Headquarters: Pleasanton, CA

10x Genomics employees: 101-250

Funding: $113M USD

Founded: 2012

Founders: Serge Saxonov, Ben Hindson


 

10x Genomics News 

The researchers used 10X Genomics' linked-read genome sequencing approach to home in on rearrangements that affect the androgen receptor locus and its enhancer.

The effort aims to sequence at least 150 animals, plants, and microbes selected for their potential benefits to Canada in the next three years.

The company said it will use the proceeds for technology development and to expand its global footprint, among other things.

Inscripta is creating its own market and customer base while also utilizing the expertise of its customers to refine and improve its products.

The company plans to launch a single-cell CNV assay, a single cell ATAC-seq assay, and a single-cell feature barcoding assay later this year.

An Australian team used Pacific Biosciences long reads, 10X Genomics linked reads, and Bionano Genomics mapping to assemble a desert dingo genome de novo.

Companies in the life science tools and molecular diagnostics spaces provided updates on their businesses at the 36th annual JP Morgan Healthcare Conference this week in San Francisco.

The companies will work together on a new sequencing-based NIPT technology developed by 10x Genomics for the Chinese market.

The combined workflow will enable the analysis of archival dried blood spots using 10x Genomics' linked-read technology, according to the companies.

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.